Connect with us

Hi, what are you looking for?

Jewish Business News

IPOs

NeuroDerm’s IPO Comes Up Short

NeuroDerm Ltd. brochure image

Israel’s NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, held a less than stellar IPO on the NASDAQ, selling 4.5 million shares at a price of just $10 per share. The represented a total of $45 million raised for a company valuation of only $164 million.

NeuroDerm had previously disclosed an expected valuation of $290 million as it had hoped to raise as much as $72 million from its IPO. But the company could end up with more than $50 million in new funds as it has granted the underwriters of the IPO a 30-day option to purchase up to an additional 675, 000 ordinary shares.

The company will use the new funds for the continued development of its support ND0612H and ND0612L, two mid-stage products that mete out respective high and low doses of the Parkinson’s treatments levodopa and carbidopa.

It is one of 70 bio-med firms to go public in The U.S. so far this year alone.

Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners acted as co-managers for the proposed offering.

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement
cialis